Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21
22 juin 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.Studies are...
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
11 mars 2021 05h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting...
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
26 févr. 2021 08h23 HE
|
Novavax, Inc.
Agreement includes COVID-19 vaccine technology transfer to Takeda for local manufacturing and commercialization in JapanTakeda doses first participant in immunogenicity and safety study to support...
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
16 févr. 2021 07h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James Sapirstein
24 nov. 2020 08h17 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
10 sept. 2020 05h46 HE
|
ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01 Company Receives FDA Approval for US IND ...
Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo
03 sept. 2020 08h30 HE
|
Auris Medical AG
Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trialImprovement 1.9 to 2.4 times greater with highest dose than with placeboTrial to proceed with Part B to test AM-125...
Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo
29 juil. 2020 08h30 HE
|
Auris Medical AG
Dose escalation completed as last patient enrolled into Part A of TRAVERS studyInterim results to be announced in Q3 of 2020 Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ:...
Eric Traut First Attorney to Receive Project Youth Barnes Award and ABOTA Trial Lawyer of the Year Honor in Same Year
09 déc. 2019 06h00 HE
|
Eric Traut
SANTA ANA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Attorney Eric Traut will be the first attorney ever to receive the highest award from Orange County American Board of Trial Advocates and the...
Cavitation Technologies Announces Update on Produced Water Treatment System Trial
26 août 2019 09h00 HE
|
Cavitation Technologies, Inc
CHATSWORTH, CA, Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Cavitation Technologies, Inc. (CTi) (OTCQB: CVAT) (BERLIN: WTC), is pleased to announce its completion of successful trials of...